This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
=== Government === Official Government web portal – gateway to government sites Presidency Archived 15 July 2025 at the Wayback Machine – official website of the president of Somalia Prime Minister – official website of the prime minister of Somalia Senate – official website of the Senate of Somalia Parliament – official website of the Federal Parliament of Somalia Statistics – official website of Somalia National Bureau of Statistics
=== Cultivation === Chili peppers are the shiny, brightly coloured fruits of species of Capsicum. Botanically they are berries. The plants are small, 20 to 60 centimetres (7.9 to 23.6 in) depending on variety, making them suitable for growing in pots, greenhouses, or commercially in polytunnels. The plants are perennial, provided they are protected from cold. The fruits can be green, orange, red, or purple, and vary in shape from round and knobbly to smooth and elongated. If the fruits are picked green and unripe, more flowers develop, yielding more fruit; fruits left on the plant can become hotter in taste, and acquire their ripe coloration, at the price of a reduced harvest. Ideal growing conditions for peppers include a sunny position with warm, loamy soil, ideally 21 to 29 °C (70 to 84 °F), that is moist but not waterlogged. The seeds germinate only when warm, close to 21 °C (70 °F). The plants prefer warm conditions, but can tolerate temperatures down to 12 °C (54 °F); and are sensitive to cold. The flowers can self-pollinate. However, at extremely high temperatures, 30 to 38 °C (86 to 100 °F), pollen loses viability, and its flowers are much less likely to result in fruit. For flowering, Capsicum is a non-photoperiod-sensitive crop. Chilies are vulnerable to pests including aphids, glasshouse red spider mite, and glasshouse whitefly, all of which feed on plant sap. Common diseases include grey mould caused by Botrytis cinerea; this rots the tissues and produces a brownish-grey mould on the surface.
=== Electrodiagnostic testing === Electromyography (EMG) and nerve conduction studies help distinguish myopathic from neurogenic causes of weakness and may show characteristic myopathic motor unit potentials or myotonic discharges. A myopathic EMG combined with proximal weakness and hyperCKemia substantially increases the likelihood of a positive muscle biopsy, although a normal EMG does not exclude myopathy.
Bahzad Al-Akhras, a psychiatrist in Al-Mawasi, described the psychological impacts of the war on children, stating they were "learning that nothing is secure, nothing is stable. They have learnt to continuously escape, not to trust others, not to trust life itself." Caitlin Procter, a researcher at the Centre on Conflict, Development and Peacebuilding in Geneva, highlighted the severe psychological impact on children in Gaza. Some have witnessed the brutal killings of their parents by soldiers, while others have seen their homes destroyed by bombings. Many children endure extreme conditions of cold, hunger, and loneliness, spending days wandering the streets alone. The overwhelming situation has left even mental health experts in Gaza feeling helpless and in need of support. In Rafah, located in the southern part of the Palestinian territory, Karyn Beattie from the NGO Save the Children described the dire situation where displaced Gazan children, some as young as pre-teens, are forced to work as breadwinners, selling aid items to afford basic necessities. By October 2025, large numbers of children were seen on the streets during the day, many showing unusually aggressive behavior. The psychological damage suffered by Gaza's younger generation is described as beyond measure.
Sources: en.wikipedia.org
=== Release === Generally, a neurotransmitter is released via exocytosis at the presynaptic terminal in response to an electrical signal called an action potential in the presynaptic neuron. However, low-level "baseline" release also occurs without electrical stimulation. Neurotransmitters are released into and diffuse across the synaptic cleft, where they bind to specific receptors on the membrane of the postsynaptic neuron.
The indigenous inhabitants of the Maluku Islands are Melanesian in origin and have been living in the Maluku archipelago since at least 30,000 BCE. However, due to later Austronesian migration waves from around 5,000 - 2,000 BCE, genetic studies detail the presence of varying levels of Austronesian mitochondrial DNA in populations on different islands in Maluku, whereas paternal genetic structure remains predominantly Melanesian in its make-up within the region. This explains a primarily maternal Austronesian influence on the Melanesian population that influenced the development of typical socio-linguistic elements and other areas within the Moluccan culture, making Malayo-Polynesian languages dominating in most of the region, with the exception of some areas where languages belonging to the West Papuan language group are still prevalent. Later added to this were several Dutch, Chinese, Portuguese, Spanish, Arabian and English influences, due to colonization, intermarriage with foreign traders during the Silk-route era and Middle Ages, and even with European soldiers during the World Wars. A small number of German descendants was added to Moluccan population, especially in Ambon, along with arrival of Protestant Missionaries since 16th century. After the Japanese occupation of the Dutch East Indies during World War II, the Netherlands wished to restore the previous colonial system; however, indigenous Indonesians opposed this. A struggle for independence led by Sukarno and his rebel forces broke out in 1945 and lasted until 1950.
Irini Sereti is a Greek scientist and physician. She is chief of the HIV pathogenesis section at the National Institute of Allergy and Infectious Diseases. Sereti researches immune reconstitution inflammatory syndrome, idiopathic CD4 lymphocytopenia, and immune-based therapeutic strategies of HIV investigation.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.